Day: January 9, 2026

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending positive results, an NDA submission is planned for the second half of 2026 Accelerating U.S. launch readiness for QTORIN™ rapamycin for microcystic LMs which has the potential to become the first FDA-approved therapy and a first-line, standard-of-care treatment for this serious, lifelong disease affecting an estimated more than 30,000 diagnosed patients in the U.S. Following positive Phase 2 results for QTORIN™ rapamycin for the treatment of cutaneous venous malformations announced in December 2025, requested a Preliminary Breakthrough Therapy Designation Advice meeting with the U.S. Food and...

Seasoned Capital Markets and Financial Executive to Drive Strategic Growth and Market Expansion BELVIDERE, NJ, Jan. 09, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agriculture (CEA) solutions and sustainable, locally grown organic produce, today announced that Matthew McConnell, a member of the Company’s Board of Directors, has joined Edible Garden’s senior leadership team full time as Executive Vice President Strategic Partnerships, effective immediately. In this role, Mr. McConnell will be responsible for advancing the Company’s strategic initiatives, strengthening relationships with investors and partners, and supporting long-term growth objectives across key channels. Mathew has worked on Wall Street for over 40...

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) — Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase agreements with several investors. Ping An Biomedical Co., Ltd. has entered into a series of share purchase agreements from several investors: Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor. This round of investment further strengthens the company’s long-term development in biopharmaceutical R&D, medical technology, and innovation. Yao Jinbo of 58 Group: An Entrepreneur with a Proven Track Record of Capturing Megatrends As one...

Celebration, FL, Jan. 09, 2026 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech enterprise, today announced an initial closing of an $11,000,000 note under its previously announced $250 million private placement convertible note facility (the “Note Facility”). The Company’s total available financing capacity, including the initial closing, is $1.25 billion when combined with its existing $1 billion equity purchase facility. La Rosa will deploy this capital to establish a strategic reserve, providing the liquidity and financial agility to scale its AI infrastructure strategy and develop a premium real estate portfolio of advanced data center facilities optimized for AI workloads.  Since the initial announcement of these facilities, the Company has been evaluating several...

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, the Company’s investigational gene therapy for the treatment of Huntington’s disease. “We look forward to a constructive discussion with the FDA as we work toward a timely resolution regarding an accelerated approval pathway for AMT-130,” said Matt Kapusta, chief executive officer at uniQure. “The Huntington’s disease community, including patients and clinicians, has emphasized the profound unmet medical need and the importance...

MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026, at The Westin St. Francis in San Francisco, CA. “Year over year, Ocugen’s presence at the JPM Healthcare Conference has evolved and we are delighted to share the potential of our modifier gene therapy platform along with clinical development progress,” said Dr. Musunuri. “This premier conference is the optimal way to kick off Ocugen’s catalyst-rich 2026 and engage in critical conversations with potential strategic partners and the investment community.” In addition to Dr. Musunuri’s...

Til Nasdaq Copenhagen A/S        GlobeNewswire                                 Humlebæk, den 9. december 2026                                                                               Selskabsmeddelelse nr. 1/2026                         Finanskalender for 2026 Hermed finanskalender for 2026 for SKAKO A/S: Årsrapport for 2025                Torsdag den 26. marts 2026 Ordinær generalforsamling                 Fredag 17. April 2026 Kvartalsmeddelelse for 1. kvartal 2026         Torsdag 21. maj 2026 Delårsrapport for 1. halvår 2026        Torsdag 20. august 2026 Kvartalsmeddelelse for 3. kvartal 2026        Fredag 23. oktober 2026 Med venlig hilsen SKAKO A/S Jens Wittrup WillumsenBestyrelsesformandTlf.: 23 47 56 40

SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company’s Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. “The accelerated enrollment pace in the ZEPHYR trial allows us to narrow our timing guidance to the third quarter of 2026,” said Chris Kroeger, co-Founder and Chief Executive...